NZ719536B2 - The crystalline forms of temozolomide and the method for preparing same - Google Patents

Abstract

Provided in the present invention are a new method for preparing the crystalline forms of Temozolomide and three types of crystalline form of Temozolomide by the method. Said method comprises the following steps: a Temozolomide is dissolved into dimethyl sulphoxide, a second organic solvent is added for recrystallization to prepare the crystalline forms of Temozolomide, wherein the second organic solvent is an alcohol, a ketone, a halohydrocarbon or an ester. for recrystallization to prepare the crystalline forms of Temozolomide, wherein the second organic solvent is an alcohol, a ketone, a halohydrocarbon or an ester.

Description

THE CRYSTALLINE FORMS OF TEMOZOLOMIDE AND THE METHOD FOR PREPARING SAME FIELD OF THE INVENTION The present invention belongs to the pharmaceutical field and relates to crystalline forms of pharmaceutical compound. More specifically, the present invention relates to crystalline forms of an anti-tumor drug Temozolomide and the method for preparing thereof.

BACKGROUND OF THE INVENTION Temozolomide (TMZ) is an alkylating anti-tumor drug containing an imidazotetrazine ring with an anti-tumor activity. Its chemical structure is presented as follows: Temozolomide belongs to a pro-drug with no activity. It is usually converted to the active compound MITC (5-(3-methyltriazenyl)-imidazolecarboxamide) under a physiological pH level via a non-enzymatic pathway, and MITC is further hydrolyzed to an active metabolite, showing its anti-tumor activity. In theory, the anti-tumor activity of MTIC is mainly produced by major DNA alkylation (methylation) with the 6 oxygen atom of guanine. Also, it can have secondary additional alkylation with the 7 nitrogen atom of guanine. Therefore, the subsequent cytotoxicity is considered to have the relationship with these abnormally-repaired methyl compounds.

Temozolomide compounds have been already synthesized. In recent years, however, it is continuously found that its new crystalline forms have excellent medicinal value. For example, U.S. patent US5260291 disclosed Temozolomide polymorphs prepared by using the following three different solvent systems: acetone and water (3: 1), acetone and water (1: 3), and water. Chinese Journal of Pharmaceuticals reproduced the method of U.S.

Patent US5260291, and reported the relevant data; US 20050187206 disclosed the methods for preparing various crystalline forms of Temozolomide by using a variety of solvents, such as pyridine, ethanol, acetone etc.; WO2008111092 disclosed Temozolomide monohydrate, prepared by the solvent of acetone and water (3:1); Chinese patent CN201110201186.3 disclosed a type of crystalline form of Temozolomide prepared by using a mixed solvent of acetone, acetonitrile and water.

The afore-mentioned methods have a problem caused by the solubility of TMZ, i.e. a large amount of solvent, which is up to a few times or even hundreds of times of Temozolomide, are required for dissolution, for example, in US20050187206, the amount of ethanol reached 270 times the amount of Temozolomide (v/w), and the amount of acetone used even reached more than 300 times the amount of Temozolomide (v/w).

Alternatively, although the volume of the solvent is more than 10 times the amount of Temozolomide, the yield is low, thus it is unsuitable for industrial production. In addition, the crystalline forms prepared by the above-mentioned methods are unstable, e.g. in US20050187206, crystalline Form I of Temozolomide was transformed into crystalline Form II under a condition of being heated to approximately 30 ℃.

Therefore, it is necessary to find a stable crystalline form of Temozolomide for medicine application, (27558565_1):CLNDW specifically as an active pharmaceutical ingredient (API) in a solid pharmaceutical. In addition, the solvents used in the recrystallization methods of Temozolomide in the prior art were short of specificity, so that a small amount of impurities was contained in the obtained crystalline forms of Temozolomide. As a result, the application was affected.

CONTENT OF THE INVENTION In order to solve the above problems, the present invention provides a novel method for preparing crystalline forms of Temozolomide and the crystalline forms prepared by the method.

According to the first aspect, the present invention provides a novel method for preparing crystalline forms of Temozolomide, characterized in that, the method comprises the following steps: dissolving Temozolomide in dimethylsulfoxide (DMSO), into which a second organic solvent is added for recrystallization, whereby the crystalline forms of Temozolomide are prepared. Wherein, the second organic solvent is an alcohol, a ketone, a halohydrocarbon or an ester. Preferably, the second organic solvent is ethanol, methanol, isopropanol, acetone, dichloromethane, ethyl acetate or glycol.

The method of the present invention for preparing crystalline forms of Temozolomide comprises the following steps: Temozolomide is prepared, into which DMSO with 7-20 times the amount of the Temozolomide (v/w) is added, the mixture of Temozolomide and DMSO is stirred and heated to make the Temozolomide dissolved, then a second organic solvent with 5-30 times the amount of the Temozolomide (v/w) is added, stirred, cooled down, crystallized by stirring, filtered to give the crystalline forms, and the resultant crystalline forms are washed by using the second organic solvent with 2-10 times the amount of the Temozolomide (v/w), and dried in vacuum to give the crystalline forms of Temozolomide.

More specifically, the method of the present invention for preparing crystalline forms of Temozolomide comprises the following steps: Temozolomide is prepared, into which DMSO with 7-15 times the amount of the Temozolomide (v/w) is added, the mixture of Temozolomide and DMSO is stirred and heated to 60-140°C to make the Temozolomide dissolved, then a second organic solvent with 7-20 times the amount of the Temozolomide (v/w) is added, stirred for 5-15min, cooled down to 10-15°C, crystallized for 4 hours by stirring, filtered to give the crystalline forms, and the resultant crystalline forms are washed by using the second organic solvent with 2-5 times the amount of the Temozolomide (v/w), and dried in vacuum to give the crystalline forms of Temozolomide.

It should be noted that, in the method of the present invention for preparing crystalline forms of Temozolomide, no special requirements are needed on the stirring equipment and stirring speed during the formation of the three crystalline forms. Conventional stirring equipment and stirring speed can be used for preparing the crystalline forms.

The crystalline forms prepared by the method of the present invention are identified and confirmed to be three crystalline forms: Form A, Form B and Form C.

Wherein, when the second organic solvent is selected from ethanol or methanol, the crystalline forms are identified to be the same form and designated as Form A; when the second organic solvent is selected from isopropanol, acetone, dichloromethane or ethyl acetate, the crystalline forms are identified to be the same form and designated as Form B; when the second organic solvent is glycol, the crystalline form is designated as Form C. (27558565_1):CLNDW MODE OF CARRYING OUT THE INVENTION The following specific parameters are used to describe various crystalline forms of the present invention. In the present invention, X-ray Powder Diffraction (XRPD), Thermo gravimetry-Differential Thermal Analysis (TG-DTA) and Infra-Red (IR) measurement conditions are presented as follows: XRPD: Apparatus: Savitzkey-Golay type X-ray Diffractometer, test conditions: 40kv 100mA; Slit: DS/SS = 1 °, RS = 0.3mm; Step: 0.02; target type: copper target, 1.5405Å; Range: 3-50°; scan rate: 8°/min.

TG-DTA: Apparatus: Rigaku PTC-10A TG-DTA analyzer; range: 7mg; Temperature range: room temperature-300°C; heating rate: 10°C/min; DTA range: ±25μv.

Apparatus: SHIMADZU FTIR-8400S FT/IR type infrared spectroscopy, wave number was corrected by infrared absorption peak of polystyrene film; Method: KBr tablet method, recording spectrum in a range of 4000-400cm .

In one embodiment of the present invention, when the second organic solvent is ethanol, the obtained crystalline form of Temozolomide is named as Form A0 type, characterized by powder X-ray diffraction spectrum comprising characteristic diffraction peaks expressed in terms of 2θ at 10.740.2, 14.54 0.2, 26.400.2, 28.66 0.2 and 29.74 0.2. Specific X-ray diffraction data are shown in Table 1 and the X-ray diffraction pattern is shown in Fig. 1.

Table 1 Characteristic peak parameters of X-ray diffraction pattern of Form A0 Nos. 2θ d value Relative intensity I/I 1 5.320 16.5976 3 2 10.740 8.2306 49 3 13.060 6.7733 4 4 14.040 6.3026 6 14.540 6.0870 100 6 16.180 5.4735 15 7 16.660 5.3169 7 8 17.520 5.0578 4 9 17.880 4.9568 15 19.000 4.6670 15 11 19.480 4.5531 5 12 20.580 4.3121 4 13 21.260 4.1757 9 14 21.500 4.1297 14 23.640 3.7604 10 16 25.120 3.5421 5 17 26.400 3.3732 31 18 27.060 3.2924 5 19 27.640 3.2247 6 28.660 3.1122 33 21 29.440 3.0315 10 22 29.740 3.0016 20 23 30.220 2.9550 8 (27558565_1):CLNDW 24 32.200 2.7776 8 32.520 2.7510 8 26 33.300 2.6884 4 27 34.460 2.6005 3 28 35.600 2.5198 6 29 36.140 2.4833 4 38.220 2.3528 4 31 39.580 2.2751 5 32 40.780 2.2109 4 33 41.740 2.1622 4 34 43.380 2.0842 5 44.260 2.0448 9 36 47.700 1.9050 5 37 48.600 1.8718 4 As shown in TG-DTA spectrum, Form A0 has an exothermic peak at 206 ℃(Fig. 8).

As shown in the infrared absorption spectrum data, Form A0 has characteristic absorption peaks at 3423.41, 3388.70, 3114.82, 1755.10, 1728.10, 1681.81, 1452.30, 1265.22 and 948.91cm (Fig. 15).

In another embodiment of the present invention, when the second organic solvent is methanol, the resultant crystalline form of Temozolomide is named as Form A1, characterized by powder X-ray diffraction spectrum comprising characteristic diffraction peaks expressed in terms of 2θ at 10.72 0.2, 14.58 0.2, 17.900.2, 26.44 0.2 and 28.68 0.2. Specific X-ray diffraction data are shown in Table 2, and the X-ray diffraction pattern is shown in Fig. 2.

Table 2 Characteristic peak parameters of X-ray diffraction pattern of Form A1 Nos. 2θ d value Relative intensity I/I 1 7.420 11.9042 2 2 10.720 8.2459 10 3 13.260 6.6716 4 4 14.100 6.2759 6 14.580 6.0704 100 6 16.180 5.4735 4 7 16.680 5.3106 4 8 17.560 5.0464 2 9 17.900 4.9513 12 18.980 4.6719 7 11 19.480 4.5531 2 12 20.580 4.3121 2 13 21.300 4.1680 5 14 21.520 4.1259 5 22.120 4.0153 1 16 23.660 3.7573 5 17 25.120 3.5421 3 18 26.200 3.3985 8 19 26.440 3.3682 17 27.100 3.2877 3 21 27.640 3.2247 4 22 28.680 3.1100 15 23 29.480 3.0274 9 24 29.780 2.9976 8 30.220 2.9550 5 (27558565_1):CLNDW 26 31.340 2.8519 3 27 32.240 2.7743 4 28 32.540 2.7494 3 29 33.360 2.6837 2 34.500 2.5975 2 31 35.620 2.5184 3 32 36.160 2.4820 2 33 39.580 2.2751 2 34 40.800 2.2098 2 41.760 2.1612 2 36 43.060 2.0989 2 37 47.700 1.9050 3 As shown in TG-DTA spectrum, Form A1 has an exothermic peak at 202℃ (Fig. 9).

As shown in infrared absorption spectrum data, Form A1 has characteristic absorption peaks at 3423.41, 3388.70, 3112.89, 1755.10, 1728.10, 1674.10, 1452.30, 1265.22 and 948.91cm (Fig. 16).

By comparing the powder X-ray diffraction data, TG-DTA data and infrared absorption data between Form A0 and Form A1, it can be identified that both ones should be the same crystalline form, which is totally referred to as crystalline Form A.

In another embodiment of the present invention, when the second organic solvent is isopropanol, the resultant crystalline form of Temozolomide is named as Form B0, characterized by powder X-ray diffraction spectrum comprising characteristic diffraction peaks expressed in terms of 2θ at 7.34 0.2, 14.700.2, 22.98 0.2, 23.820.2 and 28.10 0.2. Specific X-ray diffraction data are shown in Table 3 and the X-ray diffraction pattern is shown in Fig. 3.

Table 3 Characteristic peak parameters of X-ray diffraction pattern of Form B0 Nos. 2θ d value Relative intensity I/I 1 7.340 12.0338 92 2 10.800 8.1850 3 3 12.740 6.9427 2 4 14.020 6.3116 19 14.700 6.0211 100 6 16.080 5.5073 2 7 17.580 5.0407 3 8 17.920 4.9458 2 9 18.900 4.6915 6 19.440 4.5624 9 11 20.640 4.2997 2 12 22.160 4.0081 9 13 22.560 3.9380 4 14 22.980 3.8669 15 23.820 3.7324 25 16 24.420 3.6421 5 17 25.940 3.4320 11 18 26.480 3.3632 4 19 28.100 3.1729 24 28.740 3.1037 4 21 29.440 3.0315 5 22 29.760 2.9996 5 23 31.000 2.8824 12 24 32.920 2.7185 6 (27558565_1):CLNDW 33.480 2.6743 9 26 34.000 2.6346 3 27 35.620 2.5184 3 28 37.360 2.4050 11 29 37.980 2.3672 3 40.300 2.2361 4 31 45.520 1.9910 8 32 47.480 1.9133 5 33 47.940 1.8960 4 34 48.340 1.8813 4 48.780 1.8653 4 As shown in TG-DTA spectrum, Form B0 has an exothermic peak at 203℃ (Fig. 10).

As shown in infrared absorption spectrum data, Form B0 is characterized in that it has characteristic absorption peaks at 3388.70, 3114.82, 1758.96, 1681.81, 1452.30, 1265.22, 950.84 and 736.76cm (Fig. 17).

In another embodiment of the present invention, when the second organic solvent is acetone, the resultant crystalline form of Temozolomide is named as Form B1, characterized by powder X-ray diffraction spectrum comprising characteristic peaks expressed in terms of 2θ at 7.30 0.2, 14.70 0.2, 18.88 0.2, 23.76 0.2, 28.060.2 and 29.42 0.2. Specific X-ray diffraction data are shown in Table 4 and the X-ray diffraction pattern is shown in Fig. 4.

Table 4 Characteristic peak parameters of X-ray diffraction pattern of Form B1 Nos. 2θ d value Relative intensity I/I 1 7.300 12.0996 100 2 10.740 8.2306 5 3 11.120 7.9502 3 4 12.680 6.9754 5 13.940 6.3476 30 6 14.700 6.0211 78 7 16.080 5.5073 3 8 17.600 5.0350 11 9 17.900 4.9513 4 18.880 4.6964 44 11 19.360 4.5810 19 12 20.000 4.4359 7 13 20.660 4.2956 9 14 22.140 4.0117 7 22.500 3.9483 11 16 22.880 3.8836 42 17 23.760 3.7417 75 18 24.340 3.6539 12 19 25.860 3.4424 10 26.380 3.3757 8 21 27.140 3.2829 4 22 28.060 3.1773 69 23 28.680 3.1100 12 24 29.420 3.0335 44 30.960 2.8860 32 26 31.500 2.8378 4 27 32.840 2.7250 6 28 33.140 2.7010 10 29 33.380 2.6821 18 (27558565_1):CLNDW 33.900 2.6421 7 31 34.540 2.5946 5 32 35.560 2.5225 5 33 37.340 2.4062 10 34 37.640 2.3878 5 39.320 2.2895 4 36 40.220 2.2403 6 37 40.800 2.2098 4 38 41.820 2.1582 5 39 42.960 2.1036 5 40 43.540 2.0769 4 41 44.640 2.0282 4 42 45.420 1.9952 6 43 47.400 1.9164 7 44 48.280 1.8835 6 45 48.720 1.8675 5 As shown in TG-DTA spectrum, Form B1 has an exothermic peak at 202℃ (Fig. 11).

As shown in infrared absorption spectrum data, Form B1 has characteristic absorption peaks at 3388.70, 3114.82, 1758.96, 1728.10, 1681.81, 1452.30, 1265.22, 952.77 and 736.76cm (Fig. 18).

In another embodiment of the present invention, when the second organic solvent is dichloromethane, the resultant crystalline form of Temozolomide is named as Form B2, characterized by powder X-ray diffraction spectrum comprising characteristic peaks expressed in terms of 2θ at 7.320.2, 14.02 0.2, 14.700.2, 22.940.2 and 23.78 0.2. Specific X-ray diffraction data are shown in Table 5 and the X-ray diffraction pattern is shown in Fig. 5.

Table 5 Characteristic peak parameters of X-ray diffraction pattern of Form B2 Nos. 2θ d value Relative intensity I/I 1 7.320 12.0666 100 2 10.620 8.3234 1 3 12.720 6.9536 2 4 14.020 6.3116 14 14.700 6.0211 99 6 17.580 5.0407 3 7 18.900 4.6915 4 8 19.380 4.5764 6 9 22.120 4.0153 8 22.940 3.8736 11 11 23.780 3.7386 24 12 24.400 3.6450 5 13 25.880 3.4398 9 14 28.120 3.1707 7 29.500 3.0254 4 16 29.880 2.9878 5 17 30.960 2.8860 10 18 32.920 2.7185 7 19 33.420 2.6790 8 33.920 2.6406 2 21 35.580 2.5211 2 22 37.340 2.4062 10 23 37.940 2.3696 4 24 40.260 2.2382 3 (27558565_1):CLNDW 42.880 2.1073 2 26 45.500 1.9919 6 27 47.440 1.9148 4 28 47.920 1.8968 4 29 48.280 1.8835 4 48.760 1.8661 3 As shown in TG-DTA spectrum, Form B2 has an exothermic peak at 205℃ (Fig. 12).

As shown in infrared absorption spectrum data, Form B2 has characteristic absorption peaks at 3388.70, 3114.82, 1758.96, 1735.81, 1731.96, 1677.95, 1452.30, 1265.22, 952.77 and 736.76cm (Fig. 19).

In another embodiment of the present invention, when the second organic solvent is ethyl acetate, the resultant crystalline form of Temozolomide is named as Form B3, characterized by powder X-ray diffraction spectrum comprising characteristic peaks expressed in terms of 2θ at 7.36 0.2, 14.060.2, 14.74 0.2, 23.00 0.2 and 23.860.2. Specific X-ray diffraction data are shown in Table 6 and the X-ray diffraction pattern is shown in Fig. 6.

Table 6 Characteristic peak parameters of X-ray diffraction pattern of Form B3 Nos. 2θ d value Relative intensity I/I 1 7.360 12.0011 100 2 11.200 7.8936 2 3 12.780 6.9210 3 4 14.060 6.2937 38 14.740 6.0049 93 6 16.120 5.4938 3 7 17.640 5.0237 5 8 18.940 4.6817 13 9 19.460 4.5577 13 20.080 4.4184 3 11 20.740 4.2792 3 12 22.180 4.0046 7 13 22.580 3.9345 6 14 23.000 3.8636 27 23.860 3.7263 38 16 24.500 3.6304 8 17 25.940 3.4320 12 18 26.560 3.3533 2 19 28.180 3.1641 21 28.800 3.0974 4 21 29.520 3.0234 8 22 31.040 2.8788 18 23 32.960 2.7153 6 24 33.480 2.6743 10 34.020 2.6331 3 26 35.660 2.5157 3 27 37.380 2.4038 7 28 37.980 2.3672 3 29 40.320 2.2350 4 44.640 2.0282 2 31 45.520 1.9910 5 32 47.480 1.9133 5 33 48.360 1.8805 4 34 48.800 1.8646 4 (27558565_1):CLNDW As shown in TG-DTA spectrum, Form B3 has an exothermic peak at 200℃ (Fig. 13).

As shown in infrared absorption spectrum data, Form B3 has characteristic absorption peaks at 3388.70, 3114.82, 1751.24, 1735.81, 1728.10, 1674.10, 1452.30, 1265.22, 952.77, 730.97 and 711.68cm (Fig. 20).

By comparing the powder X-ray diffraction, TG-DTA data and infrared absorption data of B0, B1, B2 and B3 crystalline forms, it can be identified that these four ones should be the same crystalline form, which is totally referred to as crystalline Form B.

In another embodiment of the present invention, when the second organic solvent is glycol, the resultant crystalline form of Temozolomide is named as Form C, characterized by powder X-ray diffraction spectrum comprising characteristic peaks expressed in terms of 2θ at 11.460.2, 13.20 0.2, 19.64 0.2, 24.58 0.2 and 28.800.2. Specific X-ray diffraction data are shown in Table 7 and the X-ray diffraction pattern is shown in Fig. 7.

Table 7 Characteristic peak parameters of X-ray diffraction pattern of Form C Nos. 2θ d value Relative intensity I/I 1 10.860 8.1400 7 2 11.460 7.7151 100 3 12.140 7.2844 7 4 13.200 6.7018 19 14.680 6.0293 17 6 15.420 5.7415 4 7 16.260 5.4468 3 8 16.740 5.2917 2 9 17.120 5.1751 3 18.040 4.9132 6 11 19.100 4.6428 4 12 19.640 4.5164 22 13 21.540 4.1221 10 14 23.020 3.8603 14 23.900 3.7201 9 16 24.580 3.6187 23 17 25.400 3.5037 4 18 26.520 3.3582 10 19 26.860 3.3165 14 27.800 3.2065 6 21 28.800 3.0974 20 22 29.980 2.9781 9 23 30.900 2.8915 15 24 31.140 2.8697 10 31.480 2.8395 7 26 32.100 2.7861 7 27 33.600 2.6650 3 28 37.940 2.3696 4 29 38.600 2.3306 5 39.620 2.2729 3 31 41.340 2.1822 10 32 43.320 2.0869 4 33 43.580 2.0751 9 34 46.380 1.9561 4 46.920 1.9349 15 36 49.780 1.8302 5 (27558565_1):CLNDW As shown in TG-DTA spectrum, Form C has an exothermic peak at 201℃ (Fig. 14).

As shown in infrared absorption spectrum data, Form C has characteristic absorption peaks at 3388.70, 3112.89, 1758.96, 1731.96, 1674.10, 1454.23, 1267.14, 950.84, 736.76 and 698.18cm (Fig. 21).

According to the second aspect, the present invention also provides a pharmaceutical composition, particularly a solid pharmaceutical composition, and the pharmaceutical composition contains any one of the crystalline forms of Temozolomide of the present invention.

The API of the pharmaceutical composition is any one of the crystalline forms of Temozolomide of the present invention, and its percentage by weight in the preparations may be 0.01-99.99%, and the balanced is pharmaceutically acceptable carrier(s).

Preferably, the solid pharmaceutical composition of the present invention is solid pharmaceutical compositions for oral administration, such as tablets, capsules, granules, pills, dry powders and the like.

The usage and dosage of the pharmaceutical compositions are determined by the patient's conditions, e.g. 1-3 times per day.

Compared with the prior art, the present invention has the following advantages: (1) Improved yield rate: since DMSO belongs to an aprotic polar solvent, and Temozolomide has a large solubility in DMSO, only a small amount of the solvent is needed for purification. Addition of the second organic solvent can improve product yield rate greatly. (2) Increased purity: the organic impurities in Temozolomide have a high solubility in the second organic solvent and DSMO, especially the colored allergic impurities which are difficult to be removed by other solvents can be eliminated. Thus, the product purity increases significantly. (3) Purity and stability of the crystalline forms of Temozolomide prepared by the method of the present invention are better than those in the prior art.

The advantages of the present invention are presented by the following experimental data: I. Solubility test It should be noted that each crystalline form of Form A, Form B and Form C has similar solubility properties.

Hereinafter, Form A0, B0 and C were chosen only for illustrative purpose. 1. Solubility test of the crystalline Form A of Temozolomide (Form A0 prepared by the method of EXAMPLE 1). Solubility properties were assayed respectively by using DMSO, methanol, water, glacial acetic acid, 0.1M HCl, 0.1M NaOH and ethanol as the solvents. The results are shown in Table 8.

Table 8 Results of solubility test of crystalline Form A of Temozolomide Tested drug Amount of solvent for Amount of solvent for Solvents Solubility (mg) dissolving tested drug (ml) dissolving 1g of tested drug (ml) DMSO 10.10 0.7 70 sparingly soluble Methanol 9.98 7.0 700 Slightly soluble Water 9.84 8.0 800 Slightly soluble Glacial acetic acid 10.09 3.0 300 Slightly soluble 0.1M HCl 10.13 7 700 Slightly soluble 0.1M NaOH 9.95 3 300 Slightly soluble Ethanol 10.03 55 5500 Very slightly soluble 2. Solubility test of the crystalline form B of Temozolomide (Form B0 prepared by the method of EXAMPLE (27558565_1):CLNDW 6). Solubility properties were assayed respectively by using DMSO, methanol, water, glacial acetic acid, 0.1M HCl, 0.1M NaOH and ethanol as the solvents. The results are shown in Table 9.

Table 9 Results of solubility test of crystalline Form B of Temozolomide Tested drug Amount of solvent for Amount of solvent for Solvents Solubility (mg) dissolving tested drug (ml) dissolving 1g of tested drug (ml) DMSO 10.07 0.6 70 sparingly soluble Methanol 9.89 9.0 900 Slightly soluble Water 10.02 8.0 800 Slightly soluble Glacial acetic acid 9.99 3.0 300 Slightly soluble 0.1M HCl 9.93 8 800 Slightly soluble 0.1M NaOH 10.05 3 300 Slightly soluble Ethanol 10.13 57 5700 Very slightly soluble 3. Solubility test of the crystalline form C of Temozolomide (Form C prepared by the method of EXAMPLE 14). Solubility properties were assayed respectively by using DMSO, methanol, water, glacial acetic acid, 0.1M HCl, 0.1M NaOH and ethanol as the solvents. The results are shown in Table 10.

Table 10 Results of solubility test of crystalline Form C of Temozolomide Tested drug Amount of solvent for Amount of solvent for Solvents solubility (mg) dissolving tested drug (ml) dissolving 1g of tested drug (ml) DMSO 9.95 0.8 80 sparingly soluble Methanol 9.91 8.0 800 Slightly soluble Water 10.08 8.0 800 Slightly soluble Glacial acetic acid 10.21 3.0 300 Slightly soluble 0.1M HCl 10.11 8.0 800 Slightly soluble 0.1M NaOH 9.97 3.0 300 Slightly soluble Ethanol 10.17 60 6000 Very slightly soluble II. Stability test In the following test, related substances were determined as follows: HPLC method was used and chromatographic conditions were as follows: C18 column using octadecylsilane bonded silica gel as the filler, isocratic elution using methanol : 0.5% glacial acetic acid solution (10:90) as the mobile phase, and detection wavelength was at 254nm.

It should be noted that each crystalline form of Form A, Form B and Form C has similar stability properties.

Hereinafter, Form A0, Form B0 and Form C were chosen only for illustrative purpose. 1. Stability of crystalline form A of Temozolomide 1.1 Light exposure test Crystalline form A of Temozolomide (Form A0 prepared by the method of EXAMPLE 1) was exposed under th th conditions of light intensity of 4500 ± 500Lx, sampled and determined on the 5 and 10 day. The results are shown in Table 11.

Table 11 Results of crystalline Form A of Temozolomide in the strong light exposure test Time (day) Appearance and color Drying loss (%) Content (%) Related substances 0 day White powder 0.35 99.94 Not detected day White powder 0.33 99.93 Not detected day White powder 0.39 99.81 Not detected 1.2 High temperature test Crystalline form A of Temozolomide (Form A0 prepared by the method of EXAMPLE 1) was placed in 60℃ (27558565_1):CLNDW th th incubator, sampled and determined on the 5 and 10 day. The results are shown in Table 12.

Table 12 Results of crystalline Form A of Temozolomide in the high temperature test Time (day) Appearance and color Drying loss (%) Content (%) Related substances 0 day White powder 0.41 99.94 Not detected day White powder 0.38 99.63 Not detected day White powder 0.34 99.31 Not detected 1.3 High humidity test Crystalline Form A of Temozolomide (Form A0 prepared by the method of EXAMPLE 1) was placed in 25℃ th th incubator (relative humidity: 75±5%), sampled and determined on the 5 and 10 day. The results are shown in Table 13.

Table 13 Results of crystalline Form A of Temozolomide in the high humidity test Time (day) Appearance and color Weight gain of moisture absorption (%) Content (%) Related substances 0 day White powder 0 99.94 Not detected day White powder 0.32 99.73 Not detected day White powder 0.51 99.52 Not detected 1.4 Accelerated test Crystalline Form A of Temozolomide (Form A0 prepared by the method of EXAMPLE 1) was sealed by a polyethylene film bag, placed under conditions of 40±2℃ and a relative humidity of 75±5% for 6 months, st nd rd th sampled and determined at the end of the 1 , 2 , 3 and 6 month. The results are shown in Table 14.

Table 14 Results of crystalline Form A of Temozolomide in the accelerated test Time Appearance and color Content (%) Related substances 0 month White powder 99.94 Not detected 1 month White powder 99.81 Not detected 2 month White powder 99.64 Not detected 3 month White powder 99.92 Not detected 6 month White powder 99.62 Not detected As shown in the results, crystalline Form A of Temozolomide was stable in the light exposure test, the high-temperature test, the high-humidity test and the accelerated test, and there was no obvious change in the appearance and color, the drying loss, the content and the related substances. The weight gain of moisture absorption slightly increased under the high-humidity condition. 2. Stability of crystalline Form B of Temozolomide 2.1 Light exposure test Crystalline form B of Temozolomide (Form B0 prepared by the method of EXAMPLE 6) was placed, exposed th th under conditions of light intensity of 4500 ± 500Lx, sampled and determined on the 5 and 10 day. The results are shown in Table 15.

Table 15 Results of crystalline Form B of Temozolomide in the strong light exposure test Time (day) Appearance and color Drying loss (%) Content (%) Related substances (27558565_1):CLNDW 0 day White powder 0.38 99.97 Not detected day White powder 0.33 99.92 Not detected day White powder 0.29 99.95 Not detected 2.2 High temperature test Crystalline Form B of Temozolomide (Form B0 prepared by the method of EXAMPLE 6) was placed in 60℃ th th incubator, sampled and determined on the 5 and 10 day. The results are shown in Table 16.

Table 16 Results of crystalline Form B of Temozolomide in the high temperature test Time (day) Appearance and color Drying loss (%) Content (%) Related substances 0 day White powder 0.33 99.97 Not detected day White powder 0.27 99.73 Not detected day White powder 0.29 99.61 Not detected 2.3 High humidity test Crystalline Form B of Temozolomide (Form B0 prepared by the method of EXAMPLE 6) was placed in 25℃ th th incubator (relative humidity: 75±5%), sampled and determined on the 5 and 10 day. The results are shown in Table 17.

Table 17 Results of crystalline Form B of Temozolomide in the high humidity test Time (day) Appearance and color Weight gain of moisture absorption (%) Content (%) Related substances 0 day White powder 0 99.97 Not detected day White powder 0.37 99.63 Not detected day White powder 0.52 99.57 Not detected 2.4 Accelerated test Crystalline Form B of Temozolomide (Form B0 prepared by the method of EXAMPLE 6) was sealed with a polyethylene film bag and placed under conditions of 40±2℃ and a relative humidity of 75±5% for 6 months, st nd rd th sampled and determined at the end of the 1 , 2 , 3 and 6 month. The results are shown in Table 18.

Table 18 Results of crystalline Form B of Temozolomide in the accelerated test Time Appearance and color Content (%) Related substances 0 month White powder 99.97 Not detected 1 month White powder 99.71 Not detected 2 month White powder 99.82 Not detected 3 month White powder 99.73 Not detected 6 month White powder 99.85 Not detected As shown in the results, crystalline Form B of Temozolomide was stable in the light exposure test, the high-temperature, the high-humidity test and the accelerated test, and there was no obvious change in the appearance and color, the drying loss, the content and the related substances. The weight gain of moisture absorption slightly increased under the high-humidity condition. 3. Stability of crystalline Form C of Temozolomide 3.1 Light exposure test (27558565_1):CLNDW Crystalline Form C of Temozolomide (Form C prepared by the method of EXAMPLE 14) was placed, th th exposed under conditions of light intensity of 4500 ± 500Lx, sampled and determined on the 5 and 10 day.

The results are shown in Table 19.

Table 19 Results of crystalline Form C of Temozolomide in the strong light exposure test Time (day) Appearance and color Drying loss (%) Content (%) Related substances 0 day White powder 0.27 99.91 Not detected day White powder 0.30 99.90 Not detected day White powder 0.32 99.96 Not detected 3.2 High temperature test Crystalline Form C of Temozolomide (Form C prepared by the method of EXAMPLE 14) was placed in 60℃ th th incubator, sampled and determined on the 5 and 10 day. The results are shown in Table 20.

Table 20 Results of crystalline Form C of Temozolomide in the high temperature test Time (day) Appearance and color Drying loss (%) Content (%) Related substances 0 day White powder 0.35 99.91 Not detected day White powder 0.37 99.79 Not detected day White powder 0.34 99.69 Not detected 3.3 High humidity test Crystalline Form C of Temozolomide (Form C prepared by the method of EXAMPLE 14) was placed in 25℃ th th incubator (relative humidity: 75±5%), sampled and determined on the 5 and 10 day. The results are shown in Table 21.

Table 21 Results of crystalline Form C of Temozolomide in the high humidity test Time (day) Appearance and color Weight gain of moisture absorption (%) Content (%) Related substances 0 day White powder 0 99.91 Not detected day White powder 0.29 99.85 Not detected day White powder 0.47 99.63 Not detected 3.4 Accelerated test Crystalline Form C of Temozolomide (Form C prepared by the method of EXAMPLE 14) was sealed with a polyethylene film bag and placed under conditions of 40±2℃ and a relative humidity of 75±5% for 6 months, st nd rd th sampled and determined at the end of the 1 , 2 , 3 and 6 month. The results are shown in Table 22.

Table 22 Results of crystalline Form C of Temozolomide in the accelerated test Time Appearance and color Content (%) Related substances 0 month White powder 99.91 Not detected 1 month White powder 99.61 Not detected 2 month White powder 99.87 Not detected 3 month White powder 99.93 Not detected 6 month White powder 99.65 Not detected As shown in the results, crystalline Form C of Temozolomide was stable in the light exposure test, the (27558565_1):CLNDW high-temperature, the high-humidity test and the accelerated test, and there was no obvious change in the appearance and color, the drying loss, the content and the related substances. The weight gain of moisture absorption slightly increased under the high-humidity condition.

DESCRIPTION OF THE DRAWINGS Fig.1 is the X-ray diffraction pattern of Form A0 prepared by using ethanol as the second organic solvent.

Fig.2 is the X-ray diffraction pattern of Form A1 prepared by using methanol as the second organic solvent.

Fig.3 is the X-ray diffraction pattern of Form B0 prepared by using isopropanol as the second organic solvent.

Fig.4 is the X-ray diffraction pattern of Form B1 prepared by using acetone as the second organic solvent.

Fig.5 is the X-ray diffraction pattern of Form B2 prepared by using dichloromethane as the second organic solvent.

Fig.6 is the X-ray diffraction pattern of Form B3 prepared by using ethyl acetate as the second organic solvent.

Fig.7 is the X-ray diffraction pattern of Form C prepared by using glycol as the second organic solvent.

Fig.8 is the TG-DTA chart of Form A0 prepared by using ethanol as the second organic solvent.

Fig.9 is the TG-DTA chart of Form A1 prepared by using methanol as the second organic solvent.

Fig.10 is the TG-DTA chart of Form B0 prepared by using isopropanol as the second organic solvent.

Fig.11 is the TG-DTA chart of Form B1 prepared by using acetone as the second organic solvent.

Fig.12 is the TG-DTA chart of Form B2 prepared by using dichloromethane as the second organic solvent.

Fig.13 is the TG-DTA chart of Form B3 prepared by using ethyl acetate as the second organic solvent.

Fig.14 is the TG-DTA chart of Form C prepared by using glycol as the second organic solvent.

Fig.15 is the infrared absorption spectrum of Form A0 prepared by using ethanol as the second organic solvent.

Fig.16 is the infrared absorption spectrum of Form A1 prepared by using methanol as the second organic solvent.

Fig.17 is the infrared absorption spectrum of Form B0 prepared by using isopropanol as the second organic solvent.

Fig.18 is the infrared absorption spectrum of Form B1 prepared by using acetone as the second organic solvent.

Fig.19 is the infrared absorption spectrum of Form B2 prepared by using dichloromethane as the second organic solvent.

Fig.20 is the infrared absorption spectrum of Form B3 prepared by using ethyl acetate as the second organic solvent.

Fig.21 is the infrared absorption spectrum of Form C prepared by using glycol as the second organic solvent.

EXAMPLES The following examples were used to further illustrate the present invention. The method in the examples of the present invention are merely illustrative of the present invention and are not intended to limit the present invention.

EXAMPLE 1 preparation of crystalline Form A of Temozolomide 40 20g of Temozolomide was placed into a reaction bottle, into which 200ml of DMSO was added, the mixture of Temozolomide and DMSO was stirred and heated to 80 ℃ to make the Temozolomide dissolved. 300ml of ethanol was added, stirred for 5min and cooled down to 10-15℃, crystallized for 4 hours by stirring to give the crystalline form. The resultant crystalline form was filtered, washed with 40ml of ethanol and dried for 4 hours in vacuum (vacuum degree ≤−0.07Mpa) at 45-50℃ to obtain crystalline Form A0 of Temozolomide (16.4g) . (27558565_1):CLNDW The yield rate was 82%.

EXAMPLE 2 preparation of crystalline Form A of Temozolomide 20g of Temozolomide was placed into a reaction bottle, into which 140ml of DMSO was added, the mixture of Temozolomide and DMSO was stirred and heated to 140 ℃ to make the Temozolomide dissolved. 140ml of ethanol was added, stirred for 5min and cooled down to 10-15℃, crystallized for 4 hours by stirring to give the crystalline form. The resultant crystalline form was filtered, washed with 60ml of ethanol and dried for 4 hours in vacuum (vacuum degree ≤−0.07Mpa) at 45-50℃ to obtain crystalline Form A0 of Temozolomide (16.0g) .

The yield rate was 80%.

EXAMPLE 3 preparation of crystalline Form A of Temozolomide 20g of Temozolomide was placed into a reaction bottle, into which 300ml of DMSO was added, the mixture of Temozolomide and DMSO was stirred and heated to 60 ℃ to make the Temozolomide dissolved. 400ml of ethanol was added, stirred for 5min and cooled down to 10-15℃, crystallized for 4 hours by stirring to give the crystalline form. The resultant crystalline form was filtered, washed with 100ml of ethanol and dried for 4 hours in vacuum (vacuum degree ≤−0.07Mpa) at 45-50 ℃ to obtain crystalline Form A0 of Temozolomide (16.6g) . The yield rate was 83%.

EXAMPLE 4 preparation of crystalline Form A of Temozolomide 20g of Temozolomide was placed into a reaction bottle, into which 140ml of DMSO was added, the mixture of Temozolomide and DMSO was stirred and heated to 120℃ to make the Temozolomide dissolved. 100ml of methanol was added, stirred for 10min and cooled down to 10-15℃, crystallized for 4 hours by stirring to give the crystalline form. The resultant crystalline form was filtered, washed with 40ml of methanol and dried for 4 hours in vacuum (vacuum degree ≤−0.07Mpa) at 45-50 ℃ to obtain crystalline Form A1 of Temozolomide (16.7g) . The yield rate was 83.5%.

EXAMPLE 5 preparation of crystalline Form A of Temozolomide 20g of Temozolomide was placed into a reaction bottle, into which 160ml of DMSO was added, the mixture of Temozolomide and DMSO was stirred and heated to 110℃ to make the Temozolomide dissolved. 140ml of methanol was added, stirred for 10min and cooled down to 10-15℃, crystallized for 4 hours by stirring to give the crystalline form. The resultant crystalline form was filtered, washed with 60ml of methanol and dried for 4 hours in vacuum (vacuum degree ≤−0.07Mpa) at 45-50 ℃ to obtain crystalline Form A1 of Temozolomide (16.0g) . The yield rate was 80%.

EXAMPLE 6 preparation of crystalline Form B of Temozolomide 10g of Temozolomide was placed into a reaction bottle, into which 80ml of DMSO was added, the mixture of Temozolomide and DMSO was stirred and heated to 110℃ to make the Temozolomide dissolved. 200ml of isopropanol was added, stirred for 5min and cooled down to 10-15℃, crystallized for 4 hours by stirring to give the crystalline form. The resultant crystalline form was filtered, washed with 30ml of isopropanol and 40 dried for 4 hours in vacuum (vacuum degree ≤−0.07Mpa) at 45-50℃ to obtain crystalline Form B0 of Temozolomide (9.45g) . The yield rate was 94.5%.

EXAMPLE 7 preparation of crystalline Form B of Temozolomide 10g of Temozolomide was placed into a reaction bottle, into which 110ml of DMSO was added, the mixture of 45 Temozolomide and DMSO was stirred and heated to 80℃ to make the Temozolomide dissolved. 300ml of (27558565_1):CLNDW isopropanol was added, stirred for 5min and cooled down to 10-15℃, crystallized for 4 hours by stirring to give the crystalline form. The resultant crystalline form was filtered, washed with 20ml of isopropanol and dried for 4 hours in vacuum (vacuum degree ≤−0.07Mpa) at 45-50℃ to obtain crystalline Form B0 of Temozolomide (9.21g) . The yield rate was 92.1%.

EXAMPLE 8 preparation of crystalline Form B of Temozolomide 5g of Temozolomide was placed into a reaction bottle, into which 100ml of DMSO was added, the mixture of Temozolomide and DMSO was stirred and heated to 60℃ to make the Temozolomide dissolved. 150ml of acetone was added, stirred for 5min and cooled down to 10-15℃, crystallized for 4 hours by stirring to give the crystalline form. The resultant crystalline form was filtered, washed with 50ml of acetone and dried for 4 hours in vacuum (vacuum degree ≤−0.07Mpa) at 45-50 ℃ to obtain crystalline Form B1 of Temozolomide (4.1g) . The yield rate was 82%.

EXAMPLE 9 preparation of crystalline Form B of Temozolomide 5g of Temozolomide was placed into a reaction bottle, into which 60ml of DMSO was added, the mixture of Temozolomide and DMSO was stirred and heated to 70℃ to make the Temozolomide dissolved. 100ml of acetone was added, stirred for 5min and cooled down to 10-15℃, crystallized for 4 hours by stirring to give the crystalline form. The resultant crystalline form was filtered, washed with 40ml of acetone and dried for 4 hours in vacuum (vacuum degree ≤−0.07Mpa) at 45-50 ℃ to obtain crystalline Form B1 of Temozolomide (4.0g) . The yield rate was 80%.

EXAMPLE 10 preparation of crystalline Form B of Temozolomide 20g of Temozolomide was placed into a reaction bottle, into which 250ml of DMSO was added, the mixture of Temozolomide and DMSO was stirred and heated to 80℃ to make the Temozolomide dissolved. 300ml of dichloromethane was added, stirred for 5min and cooled down to 10-15℃, crystallized for 4 hours by stirring to give the crystalline form. The resultant crystalline form was filtered, washed with 50ml of dichloromethane and dried for 4 hours in vacuum (vacuum degree ≤−0.07Mpa) at 45-50℃ to obtain crystalline Form B2 of Temozolomide (19.1g) . The yield rate was 95.5%.

EXAMPLE 11 preparation of crystalline Form B of Temozolomide 20g of Temozolomide was placed into a reaction bottle, into which 200ml of DMSO was added, the mixture of Temozolomide and DMSO was stirred and heated to 80℃ to make the Temozolomide dissolved. 250ml of dichloromethane was added, stirred for 5min and cooled down to 10-15℃, crystallized for 4 hours by stirring to give the crystalline form. The resultant crystalline form was filtered, washed with 60ml of dichloromethane and dried for 4 hours in vacuum (vacuum degree ≤−0.07Mpa) at 45-50℃ to obtain crystalline Form B2 of Temozolomide (19.0g) . The yield rate was 95%.

EXAMPLE 12 preparation of crystalline Form B of Temozolomide 10g of Temozolomide was placed into a reaction bottle, into which 80ml of DMSO was added, the mixture of 40 Temozolomide and DMSO was stirred and heated to 130℃ to make the Temozolomide dissolved. 200ml of ethyl acetate was added, stirred for 5min and cooled down to 10-15℃, crystallized for 4 hours by stirring to give the crystalline form. The resultant crystalline form was filtered, washed with 50ml of ethyl acetate and dried for 4 hours in vacuum (vacuum degree ≤−0.07Mpa) at 45-50℃ to obtain crystalline Form B3 of Temozolomide (8.2g) . The yield rate was 82%. (27558565_1):CLNDW EXAMPLE 13 preparation of crystalline Form B of Temozolomide 10g of Temozolomide was placed into a reaction bottle, into which 90ml of DMSO was added, the mixture of Temozolomide and DMSO was stirred and heated to 110℃ to make the Temozolomide dissolved. 150ml of ethyl acetate was added, stirred for 5min and cooled down to 10-15℃, crystallized for 4 hours by stirring to give the crystalline form. The resultant crystalline form was filtered, washed with 40ml of ethyl acetate and dried for 4 hours in vacuum (vacuum degree ≤−0.07Mpa) at 45-50℃ to obtain crystalline Form B3 of Temozolomide (8.0g) . The yield rate was 80%.

EXAMPLE 14 preparation of crystalline Form C of Temozolomide 20g of Temozolomide was placed into a reaction bottle, into which 150ml of DMSO was added, the mixture of Temozolomide and DMSO was stirred and heated to 120℃ to make the Temozolomide dissolved. 150ml of glycol was added, stirred for 15min and cooled down to 10-15℃, crystallized for 4 hours by stirring to give the crystalline form. The resultant crystalline form was filtered, washed with 50ml of glycol and dried for 4 hours in vacuum (vacuum degree ≤−0.07Mpa) at 45-50℃ to obtain crystalline Form C of Temozolomide (18g) .

The yield rate was 90%.

EXAMPLE 15 preparation of crystalline Form C of Temozolomide 20g of Temozolomide was placed into a reaction bottle, into which 180ml of DMSO was added, the mixture of Temozolomide and DMSO was stirred and heated to 100℃ to make the Temozolomide dissolved. 200ml of glycol was added, stirred for 15min and cooled down to 10-15℃, crystallized for 4 hours by stirring to give the crystalline form. The resultant crystalline form was filtered, washed with 70ml of glycol and dried for 4 hours in vacuum (vacuum degree ≤ −0.07Mpa) at 45-50℃ to obtain crystalline Form C of Temozolomide (17.6g) .

The yield rate was 88%.

EXAMPLE 16 preparation of pharmaceutical composition as capsules containing crystalline Form A of Temozolomide (represented by Form A0 prepared by using the method of EXAMPLE 1) 1. Formulation: Specification: 5mg Crystalline Form A of Temozolomide 5g Lactose 72g Microcrystalline cellulose 15g Corn starch 65g Sodium carboxymethyl starch 5g Polyvinylpyrrolidone (PVP) proper amount Magnesium stearate 1g 1000 capsules 2. Preparation of capsules: 40 Crystalline Form A of Temozolomide, lactose, microcrystalline cellulose, corn starch and sodium carboxymethyl starch were loaded into a high-efficient wetting granulator to mix, into which 2% PVP ethanol solution (80%) was added to granulate. Resultant wet granules were dried in a fluidized bed and sized with an 18-mesh sifter, and the obtained dried granules were added with magnesium stearate, properly mixed and loaded into capsules. (27558565_1):CLNDW EXAMPLE 17 preparation of pharmaceutical composition as capsules containing crystalline Form B of Temozolomide (represented by Form B0 prepared by using the method of EXAMPLE 6) 1. Formulation: Specification: 50mg Crystalline Form B of Temozolomide 50g Lactose 50g Microcrystalline cellulose 10g Corn starch 47g Sodium carboxymethyl starch 5g Polyvinylpyrrolidone (PVP) proper amount Magnesium stearate 1g 1000 capsules 2. Preparation of capsules: Crystalline Form B of Temozolomide, lactose, microcrystalline cellulose, corn starch and sodium carboxymethyl starch were loaded into a high-efficient wetting granulator to mix, into which 2% PVP ethanol solution (80%) was added to granulate. Resultant wet granules were dried in a fluidized bed and sized with an 18-mesh sifter, and the obtained dried granules were added with magnesium stearate, properly mixed and loaded into capsules.

EXAMPLE 18 preparation of pharmaceutical composition as capsules containing crystalline Form C of Temozolomide (represented by Form C prepared by using the method of EXAMPLE 14) 1. Formulation: Specification: 50mg Crystalline Form C of Temozolomide 50g Lactose 50g Microcrystalline cellulose 10g Corn starch 47g Sodium carboxymethyl starch 5g Polyvinylpyrrolidone (PVP) proper amount Magnesium stearate 1g 1000 capsules 2. Preparation of capsules: Crystalline Form C of Temozolomide, lactose, microcrystalline cellulose, corn starch and sodium carboxymethyl starch were loaded into a high-efficient wetting granulator to mix, into which 2% PVP ethanol 40 solution (80%) was added to granulate. Resultant wet granules were dried in a fluidized bed and sized with an 18-mesh sifter, and the obtained dried granules were added with magnesium stearate, properly mixed and loaded into capsules. (27558565_1):CLNDW

Claims (6)

What is claimed is:

1. A method for preparing crystalline forms of Temozolomide, characterized in that, the method comprises the following steps: dissolving Temozolomide in dimethylsulfoxide, into which a second organic solvent 5 is added for recrystallization, whereby the crystalline forms of Temozolomide are prepared, wherein the second organic solvent is isopropanol or ethylene glycol.

2. The method according to claim 1, wherein the method comprises the following steps: Temozolomide is prepared, into which dimethylsulfoxide with 7-20 times the amount of the Temozolomide (v/w) is added, the mixture of Temozolomide and dimethylsulfoxide is stirred and heated to make the Temozolomide 10 dissolved, then the second organic solvent with 5-30 times the amount of the Temozolomide (v/w) is added, stirred, cooled down, crystallized by stirring, filtered to give the crystalline forms, and the resultant crystalline forms are washed by using the second organic solvent with 2-10 times the amount of the Temozolomide (v/w), and dried in vacuum to give the crystalline forms of Temozolomide.

3. The method according to claim 1 or claim 2, wherein the method comprises the following steps: 15 Temozolomide is prepared, into which dimethylsulfoxide with 7-15 times the amount of the Temozolomide (v/w) is added, the mixture of Temozolomide and dimethylsulfoxide is stirred and heated to 60-140°C to make the Temozolomide dissolved, then the second organic solvent with 7-20 times the amount of the Temozolomide (v/w) is added, stirred for 5-15min, cooled down to 10-15°C, crystallized for 4 hours by stirring, filtered to give the crystalline forms, and the resultant crystalline forms are washed by 20 using the second organic solvent with 2-5 times the amount of the Temozolomide (v/w), and dried in vacuum to give the crystalline forms of Temozolomide.

4. The method according to any one of claims 1-3, wherein the second organic solvent is isopropanol, the obtained crystalline form of Temozolomide has a powder X-ray diffraction spectrum comprising characteristic peaks expressed in terms of 2θ at 7.34 0.2, 14.700.2, 22.98 0.2, 23.82 0.2 and 28.10 0.2; 25 it has characteristic absorption peaks at 3388.70, 3114.82, 1758.96, 1681.81, 1452.30, 1265.22, 950.84 and 736.76cm in its infrared absorption spectrum; and it has an exothermic peak at 203℃ in its TG-DTA spectrum with a heating rate of 10°C/min.

5. The method according to any one of claims 1-3, wherein the second organic solvent is ethylene glycol; the obtained crystalline form of Temozolomide has a powder X-ray diffraction spectrum comprising 30 characteristic peaks expressed in terms of 2θ at 11.46 0.2, 13.20 0.2, 19.64 0.2, 24.58 0.2 and 28.80 0.2; it has characteristic absorption peaks at 3388.70, 3112.89, 1758.96, 1731.96, 1674.10, 1454.23, 1267.14, 950.84, 736.76 and 698.18cm in its infrared absorption spectrum; and it has an exothermic peak at 201 ℃ in its TG-DTA spectrum with a heating rate of 10°C/min.

6. The crystalline form of Temozolomide prepared by the method of claim 5 having a powder X-ray 35 diffraction spectrum with characteristic diffraction peaks as follows: Nos. 2θ d value Relative intensity I/I 1 10.860 8.1400 7 2 11.460 7.7151 100 3 12.140 7.2844 7 4 13.200 6.7018 19 5 14.680 6.0293 17 6 15.420 5.7415 4 7 16.260 5.4468 3 (27558565_1):CLNDW 8 16.740 5.2917 2 9 17.120 5.1751 3 10 18.040 4.9132 6 11 19.100 4.6428 4 12 19.640 4.5164 22 13 21.540 4.1221 10 14 23.020 3.8603 14 15 23.900 3.7201 9 16 24.580 3.6187 23 17 25.400 3.5037 4 18 26.520 3.3582 10 19 26.860 3.3165 14 20 27.800 3.2065 6 21 28.800 3.0974 20 22 29.980 2.9781 9 23 30.900 2.8915 15 24 31.140 2.8697 10 25 31.480 2.8395 7 26 32.100 2.7861 7 27 33.600 2.6650 3 28 37.940 2.3696 4 29 38.600 2.3306 5 30 39.620 2.2729 3 31 41.340 2.1822 10 32 43.320 2.0869 4 33 43.580 2.0751 9 34 46.380 1.9561 4 35 46.920 1.9349 15 36 49.780 1.8302 5 further having characteristic absorption peaks at 3388.70, 3112.89, 1758.96, 1731.96, 1674.10, 1454.23, 1267.14, 950.84, 736.76 and 698.18cm in its infrared absorption spectrum, and it has an exothermic peak at 201℃ in its TG-DTA spectrum with a heating rate of 10°C/min. (27558565_1):CLNDW